Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency¹)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Insulet Corporation (PODD) PT Raised to $234 at Barclays
November 11, 2024 5:53 AM ESTBarclays analyst Matt Miksic raised the price target on Insulet Corporation (NASDAQ: PODD) to $234.00 (from $220.00) while maintaining a Equalweight rating.
The analyst comments "PODD Rallies on Q3 Beat, Fueled by International (+$19MM), Drug Delivery (+$7MM) and Rising Expectations for the T2 Pump Launch: Mgmt delivered a strong beat to vs. our estimates and Bloomberg... More
Insulet Corporation (PODD) PT Raised to $270 at BTIG
November 8, 2024 5:13 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $270.00 (from $260.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q3 revenue of $543.9M (+25.7% y/y), beating consensus estimates of $519.5M and exceeding the ~$510-$524M sales guide. This was driven by a large beat in International Omnipod sales. U.S. Omnipod revenue of $395.6M came in ~$4M higher than expected (cons. $391.9M) while OUS Omnipod revenue of $138M was ~$15M above the Street's forecast (cons. $123.3M). Drug Delivery sales were $10.3M. The full year sales guide... More
